Skip to main content

Table 2 Dual- versus single-targeted CAR-T cell therapy for relapsed or refractory large cell lymphoma

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

  CD19/22 CD19/CD20 Axi-Cel Tisa-Cel Liso-Cel
  (Alexander)   (Zuma-1) (Juliet) (Transcend)
Phase 1 1 2 2 2
Patients (n) 33 12 111 93 256
Target CD19, CD22 CD19, CD20 CD19 CD19 CD19
Co-stim OX40, 41BB 41BB CD28 41BB 41BB
CR 52% 42% 52% 40% 53%
Median PFS (month) NA NA 5.9 3 6.8
Median OS (month) NA NA NR 12 21.1
CRS, any grade 33% 42% 93% 58% 42%
  ≥ 3 NA 0 13% 22% 2%
Neurotoxicity any grade 9% 8% 64% 21% 30%
  ≥ 3 0 0 28% 13% 10%
References [33] [34] [30] [8] [5]
  ASH 2020, #600 ASH 2020, #404 NEJM, 2017 NEJM, 2019 Lancet, 2020